期刊文献+

癌相关抗原125在恶性卵巢肿瘤治疗前后的变化 被引量:3

Change of tumor marker CA125 in patients with malignant ovarian neoplasm before and after treatment
暂未订购
导出
摘要 目的 对卵巢癌相关抗原125(CA125)在恶性卵巢肿瘤治疗前后进行不同时间段的动态监测,并探讨其临床应用价值。方法 采用电化学发光免疫分析法测定恶性卵巢肿瘤患者不同时间段的血清(或血浆)CA125值,观测其在恶性卵巢肿瘤患者治疗前后的变化。结果 在恶性卵巢肿瘤患者治疗中,术前及术后等5个不同时间段CA125的检测结果显示,术前与术后有明显差异,测定结果的均值由术前的197.2U/ml降低为术后1年的24.8U/ml;术前数据范围为10~1129U/ml、检出阳性率80.7%,术后1年数据范围降低为7.0~79.9U/ml、检出阳性率19.2%。结论 CA125的动态监测在恶性卵巢肿瘤患者治疗中有较好的临床应用价值。 Objective To investigate the clinical value of tumor marker CA125 by dynamic detecting CA125 of patients with malignant ovarian neoplasm before and after treatment. Methods Serum or plasma CA125 level of patient with malignant ovarian neoplasm was detected by electrochemoluminescence immunoassay at different time-points. Results The levels of CA125 of patients with malignant ovarian neoplasm was significantly different before and after operation. The mean level dropped down from 197.2 U/ml (10-1 129 U/ml) before operation to 24.5 U/ml (7.0-79.9 U/ml) one year after operation. And the positive rate dropped down from 80.7% to 19.2%. Conclusion The dynamic detecton of CA125 has important clinical value in the treatment of patients with malignant ovarian neoplasm.
出处 《国际检验医学杂志》 CAS 2007年第4期323-324,共2页 International Journal of Laboratory Medicine
关键词 CA-125抗原 卵巢肿瘤 CA-125 antigen Ovarian neoplasm
  • 相关文献

参考文献2

二级参考文献17

  • 1郑虹,杨晏斌,刘朝晖,廖秦平.测定血清CA_(125)水平在卵巢癌的临床意义[J].中国妇产科临床杂志,2001,2(6):342-344. 被引量:3
  • 2连利娟.卵巢肿瘤标志物及其对病情监测的意义[J].实用肿瘤杂志,1993,8(4):195-197. 被引量:9
  • 3[4]Eisenkop S M,Triendman R L,Wang H J.Secondry Cytoreductive surgery for recurrent ovarian cancer[J].Cancer,1995,76:1605-1614.
  • 4[6]Kenemans P,Yedema C A,Bon C G,et al.CA125 in gynerecologic patnologe review[J].Eur J Obstet and Reprod Biol,1993,49:145.
  • 5[7]Robert P W,Mark P C,Fengji X,et al.Combinations of multiple serum markers are superior to indiridual assays for discriminiating malignant from benign pelvicmasses[J].Gynecol Oncol,1995,59:111-116.
  • 6[10]Vander,Zee A G,Guk J M.The effect of abdominal surgery on the serum concertration of the tumor associated antigen CA125[J].Br J Obstet Gynecol,1990,97:934.
  • 7[13]Low R N,Saleh F,Song S,et al.Treated ovarian caner:Comparison of MR image with serum CA125 level and physical examination-a longitudinal study[J].Radiology,1999,211:519-528.
  • 8[17]Vander B M,Lammes F B,Vanputten W L J,et al.The prognostic value of the serum half-time of CA125 during the induction of chemotherapy[J].Gynecol Oncol,1988,39(6):307.
  • 9[18]Hogberg T,Kagedal B.Long-term follow-up of ovarian cancer with monthly determinations of serum CA125[J].Gynecol Oncol,1992,46:191-198.
  • 10[19]Gerado I,Sonia R,Andrea L,et al.Ultrasound,physical examination,and CA125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors[J].Gynecol Oncol,2001,81:63-66.

共引文献4

同被引文献31

引证文献3

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部